Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient

被引：13
|
作者：
de Ronde, A
van Dooren, M
de Rooij, E
van Gemen, B
Lange, J
Goudsmit, J
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, NATEC, NL-1105 AZ Amsterdam, Netherlands
[3] Primagen, NL-1105 BA Amsterdam, Netherlands
来源：
AIDS | 2000年 / 14卷 / 16期
关键词：
D O I：
10.1097/00002030-200011100-00038
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2632 / 2633
页数：2
相关论文
共 50 条
  • [31] Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naive seroconverters in Singapore
    Lee, C. C.
    Sun, Y. J.
    Barkham, T.
    Leo, Y. S.
    HIV MEDICINE, 2009, 10 (06) : 370 - 377
  • [32] Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains
    Zhu, QY
    Scarborough, A
    Polsky, B
    Chou, TC
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (06) : 507 - 517
  • [33] Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals
    Winand, Raf
    Theys, Kristof
    Eusebio, Monica
    Aerts, Jan
    Camacho, Ricardo J.
    Gomes, Perpetua
    Suchard, Marc A.
    Vandamme, Anne-Mieke
    Abecasis, Ana B.
    AIDS, 2015, 29 (15) : 2045 - 2052
  • [34] Thymidine analogue mutations emergence in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine
    Bocket, L
    Yazdanpanah, Y
    Ajana, F
    Gerard, Y
    Viget, N
    Goffard, A
    Alcaraz, I
    Wattre, P
    Mouton, Y
    ANTIVIRAL THERAPY, 2003, 8 (03) : U132 - U133
  • [35] Drug resistance mutations as predictors of phenotypic zidovudine resistance in HIV-1 infection
    Chen, P
    Schmit, JC
    Arendt, V
    Plesseria, JM
    Lambert, C
    Fontaine, E
    Kirpach, P
    Ninove, D
    Schneider, F
    Hemmer, R
    AIDS, 1997, 11 (12) : 1528 - 1529
  • [36] Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection
    Gracia Mateo, Maria
    del Mar Gutierrez, Maria
    Vidal, Francesc
    Domingo, Pere
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 473 - 485
  • [37] Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy
    Fox, J.
    Dustan, S.
    McClure, M.
    Weber, J.
    Fidler, S.
    HIV MEDICINE, 2006, 7 (07) : 477 - 483
  • [38] Virological responses in a patient with recent HIV-1 infection experiencing an EBV reactivation
    Din, Chiara Tassan
    Vecchi, Andrea
    Tambussi, Giuseppe
    De Rossi, Anita
    Bestetti, Arabella
    Biswas, Priscilla
    NEW MICROBIOLOGICA, 2007, 30 (03): : 283 - 285
  • [39] High prevalence and early selection of G→A HIV-1 minority species in drug-naive populations
    McCallum, M.
    Oliveira, M.
    Ibanescu, R-I
    Kramer, V. G.
    Moisi, D.
    Asahchop, E. L.
    Brenner, B. G.
    Harrigan, R.
    Xu, H.
    Wainberg, M. A.
    ANTIVIRAL THERAPY, 2013, 18 : A118 - A118
  • [40] Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection
    Metzner, Karin J.
    Scherrer, Alexandra U.
    Preiswerk, Benjamin
    Joos, Beda
    von Wyl, Viktor
    Leemann, Christine
    Rieder, Philip
    Braun, Dominique
    Grube, Christina
    Kuster, Herbert
    Boeni, Juerg
    Yerly, Sabine
    Klimkait, Thomas
    Aubert, Vincent
    Furrer, Hansjakob
    Battegay, Manuel
    Vernazza, Pietro L.
    Cavassini, Matthias
    Calmy, Alexandra
    Bernasconi, Enos
    Weber, Rainer
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (07): : 1102 - 1112
12345